

IN THE UNITED STATES PATENT AND TRADEMARK OFFICEIn Re Application of: **Wang et al.**Serial No.: **10/590,040**Group Art Unit: **1645**

Filing Date: November 21, 2006

Examiner: **Brian J Gangle**For: **T CELL IMMUNE RESPONSE INHIBITOR****VIA EFS WEB**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

**STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE
WITH 37 CFR §§ 1.821 THROUGH 1.825**

- ☒ I hereby state, in accordance with the requirements of 37 C.F.R. §1.821(f), that the contents of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 CFR §1.821(c) and (e), respectively are the same.
- ☒ I hereby state that the amendments, made in accordance with 37 CFR §1.825(a), included in the substitute sheet(s) of the Sequence Listing are supported in the application, as filed I hereby state that the substitute sheet(s) of the Sequence Listing does (do) not include new matter.

Respectfully Submitted,

/Daniel M. Scolnick, Reg.#52,201/
Daniel M. Scolnick, Ph.D.
Registration No. 52,201

Dated: January 21, 2009

PEPPER HAMILTON, LLP
400 Berwyn Park
899 Cassatt Road
Berwyn, PA 19312
610.640.7820
610.640.7835